Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elanco Animal Health filings document the disclosures of a public animal health company focused on products for farm animals and pets. The record includes Form 8-K reports on operating results, clinical or regulatory matters, capital-structure updates, credit-facility amendments, investor presentations, and restructuring-related exit or disposal activities.
Elanco's proxy materials describe board composition, shareholder voting matters, executive compensation, equity awards, and governance practices. Its filings also provide formal disclosure around material events, financial reporting, and the capital arrangements that support the company's global animal health operations.
Elanco Animal Health Inc officer Ramiro Martin Cabral reported several equity awards and related share movements. On March 1, 2026, he received an award of 42,570 stock options and separate grants of 60,053 and 20,834 shares of common stock at no cost.
The stock options and restricted stock units vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029, subject to continued service. A separate disposition of 30,150 common shares at $26.40 per share was reported as a tax-withholding transaction, leaving 269,532 common shares held directly afterward.
Elanco Animal Health executive Grace McArdle reported new equity awards and related tax withholding transactions. On March 1, 2026 she received employee stock options for 29,025 shares and grants of 30,110 and 14,205 shares of common stock at no cost. A total of 12,337 shares of common stock at $26.40 per share were disposed of to cover tax liabilities. The options and restricted stock units vest in three equal installments on March 1, 2027, 2028, and 2029.
Elanco Animal Health executive David S. Kinard reported multiple equity awards and related tax withholding transactions. On March 1, 2026 he received 19,350 employee stock options and separate grants of 33,087 and 9,470 shares of common stock at no cost. A total of 15,377 common shares were disposed of at $26.40 per share to cover tax liabilities, leaving him with 217,697 common shares directly owned. The stock options and restricted stock units vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen reported equity awards that increase his stake in the company. He received an employee stock option grant for 48,375 shares at a price of $0.0000 per share and a separate grant of 23,675 shares of common stock, both classified as grant or award acquisitions.
According to the disclosure, the stock options vest one-third on March 1, 2027, one-third on March 1, 2028, and the remainder on March 1, 2029. The restricted stock units underlying the common stock grant vest on the same schedule. After the common stock grant, his directly held common stock position is 148,652 shares, which includes 744 shares acquired under the company’s employee stock purchase plan on January 31, 2026.
Elanco Animal Health general counsel and corporate secretary Shiv O'Neill reported equity compensation changes. On March 1, 2026, O'Neill received 29,993 stock options and 33,087 shares of common stock as grant or award acquisitions, all held directly.
The filing also shows a grant of an additional 14,679 common shares and a tax-withholding disposition of 13,111 common shares at $26.40 per share to cover tax obligations. The options and restricted stock units vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Elanco Animal Health officer Ellen de Brabander reported equity compensation changes. She received an employee stock option for 51,819 shares and grants of 67,564 and 25,360 shares of common stock, all at a price of $0.00 per share. A separate 46,278-share disposition at $26.40 per share covered tax obligations. The footnotes state that both the restricted stock units and stock options vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Elanco Animal Health executive Timothy J. Bettington reported multiple equity transactions on March 1, 2026. He received an employee stock option grant for 19,350 options and several grants of common stock totaling 55,792 shares as awards. A separate transaction disposed of 18,098 common shares at $26.40 per share to cover tax withholding. The restricted stock units and stock options vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Elanco Animal Health reported that officer Rajeev A. Modi acquired a grant of 56.6301 deferred stock units on Company stock, valued at $24.98 per unit. After this award, his direct holdings in these deferred stock units total 7,651.0914 units.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. According to the company’s Executive Deferral and Stock Match Plan, these units are scheduled to settle in cash or shares after employment ends or in a specified future year.
Elanco Animal Health President and CEO Jeffrey N. Simmons reported an acquisition of deferred stock units as part of his compensation. He received 110.8583 deferred stock units on Company common stock at a reference price of $24.98 per unit, described as a grant or award. After this award, his direct holdings of deferred stock units total 19,179.7639 units. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and they settle in cash or shares following termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 7.6217 deferred stock units at a reference price of $24.98 per unit. This award increases his directly held deferred stock units to 31.0919. Each unit represents the right to receive one share of Elanco common stock or the cash equivalent, settling after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.